Multinational Drug Survival Study of Omalizumab in Patients With Chronic Urticaria and Potential Predictors for Discontinuation

医学 奥马佐单抗 中止 慢性荨麻疹 皮肤病科 药品 梅德林 跨国公司 重症监护医学 内科学 药理学 免疫学 免疫球蛋白E 抗体 政治学 法学
作者
Reineke Soegiharto,Mehran Alizadeh Aghdam,Jennifer Astrup Sørensen,Esmee van Lindonk,Ferhan Bulut Demir,Nasser Mohammad Porras,Yoshimi Matsuo,Lea Kiefer,André C. Knulst,Marcus Maurer,Carla Ritchie,Michael Rudenko,Emek Kocatürk,Roberta Fachini Jardim Criado,Stamatios Gregoriou,Tatjana Bobylev,Andreas Kleinheinz,Shunsuke Takahagi,Michihiro Hide,Ana M. Giménez‐Arnau
出处
期刊:JAMA Dermatology [American Medical Association]
卷期号:160 (9): 927-927 被引量:5
标识
DOI:10.1001/jamadermatol.2024.2056
摘要

Importance Treating patients with chronic urticaria using omalizumab has been shown to be safe and effective in randomized clinical trials. Multinational studies on long-term omalizumab performance in chronic urticaria in clinical practice settings are lacking, especially on drug survival. Drug survival, which refers to the length of time that patients are treated with a specific drug, is a comprehensive outcome covering effectiveness, safety, and patient and physician preferences. Furthermore, little is known about the reasons and potential predictors for omalizumab discontinuation. Objective To investigate omalizumab drug survival as well as reasons and potential predictors for discontinuation in a large, diverse population. Design, Setting, and Participants This international multicenter cohort study was conducted at 14 Urticaria Centers of Reference and Excellence in 10 countries, including all patients with chronic urticaria from these centers who were ever treated with omalizumab. Main Outcomes and Measures Drug survival analysis was performed to assess time to discontinuation. Patient characteristics and treatment protocols were investigated by Cox regression analysis to identify potential predictors for omalizumab discontinuation. Results In 2325 patients with chronic urticaria who started omalizumab between June 2009 and July 2022, the mean (SD) age of the cohort was 42 (6) years, and 1650 participants (71%) were female. Overall omalizumab survival rates decreased from 76% to 39% after 1 to 7 years, respectively (median survival time, 3.3 [95 % CI, 2.9-4.0] years), primarily due to discontinuation from well-controlled disease in 576 patients (65%). Ineffectiveness and adverse effects were reasons for discontinuation in a far smaller proportion of patients, totaling 164 patients (18%) and 31 patients (4%), respectively. Fast treatment response was associated with higher rates of omalizumab discontinuation due to well-controlled disease (hazard ratio, 1.45 [95% CI, 1.20-1.75]), and disease duration of more than 2 years was associated with lower rates of discontinuation due to well-controlled disease (HR, 0.81 [95% CI, 0.67-0.98]). Immunosuppressive cotreatment at the start of omalizumab and autoimmune disease was associated with a higher risk for discontinuation due to ineffectiveness (HR, 1.65 [95% CI, 1.12-2.42]). The presence of spontaneous wheals (HR, 0.62 [95% CI, 0.41-0.93]) and access to higher dosages (HR, 0.40 [95% CI, 0.27-0.58) were both associated with a lower risk for discontinuation of omalizumab due to ineffectiveness. Conclusion and Relevance This multinational omalizumab drug survival cohort study demonstrated that treatment of chronic urticaria with omalizumab in a clinical setting is effective and safe, and well-controlled disease is the main reason for treatment discontinuation. These findings on omalizumab drug survival rates and reasons and potential predictors for discontinuation may guide patients and physicians in clinical decision-making and expectation management. These results may call for the identification of biomarkers for chronic urticaria remission in complete responders to omalizumab treatment.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
更新
PDF的下载单位、IP信息已删除 (2025-6-4)

科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
852应助大方平蓝采纳,获得10
刚刚
liuz完成签到,获得积分0
1秒前
Galato发布了新的文献求助10
1秒前
1秒前
1秒前
潇洒冷菱完成签到,获得积分10
1秒前
SYLH应助别偷我增肌粉采纳,获得10
1秒前
一川烟叶完成签到,获得积分10
2秒前
无花果应助xudanhong采纳,获得10
2秒前
Sean完成签到 ,获得积分10
2秒前
2秒前
2秒前
3秒前
dypdyp应助飞云采纳,获得10
3秒前
3秒前
大兵哥发布了新的文献求助10
4秒前
gguc完成签到,获得积分10
4秒前
阿木木发布了新的文献求助30
4秒前
4秒前
SherlockHe发布了新的文献求助10
4秒前
科研韭菜发布了新的文献求助10
5秒前
饱满元灵完成签到 ,获得积分10
6秒前
dxdy完成签到,获得积分10
6秒前
我是老大应助蝉鸣采纳,获得10
6秒前
LIU完成签到,获得积分10
6秒前
是龙龙呀完成签到,获得积分10
7秒前
小马甲应助微微采纳,获得10
7秒前
7秒前
8秒前
8秒前
华仔应助Yimi采纳,获得10
8秒前
淡然的凝荷关注了科研通微信公众号
8秒前
zb完成签到,获得积分10
9秒前
下雨天完成签到,获得积分10
9秒前
ai六月份完成签到,获得积分10
9秒前
吴邪发布了新的文献求助10
9秒前
科研通AI2S应助冷静的奇迹采纳,获得10
9秒前
Song发布了新的文献求助10
10秒前
123完成签到,获得积分10
10秒前
11秒前
高分求助中
A new approach to the extrapolation of accelerated life test data 1000
Cognitive Neuroscience: The Biology of the Mind 1000
Technical Brochure TB 814: LPIT applications in HV gas insulated switchgear 1000
Immigrant Incorporation in East Asian Democracies 600
Nucleophilic substitution in azasydnone-modified dinitroanisoles 500
不知道标题是什么 500
A Preliminary Study on Correlation Between Independent Components of Facial Thermal Images and Subjective Assessment of Chronic Stress 500
热门求助领域 (近24小时)
化学 材料科学 医学 生物 工程类 有机化学 生物化学 物理 内科学 纳米技术 计算机科学 化学工程 复合材料 遗传学 基因 物理化学 催化作用 冶金 细胞生物学 免疫学
热门帖子
关注 科研通微信公众号,转发送积分 3968844
求助须知:如何正确求助?哪些是违规求助? 3513769
关于积分的说明 11169920
捐赠科研通 3249095
什么是DOI,文献DOI怎么找? 1794630
邀请新用户注册赠送积分活动 875278
科研通“疑难数据库(出版商)”最低求助积分说明 804755